Was CAR-T therapy a bystander or driver of lymphoma?

Unpacking the first published case of the rare blood cancer associated with a commercial CAR-T product, the drug Carvykti.

December 12, 2023 Check out STAT+

Sponsored By

Adobe STAT+ | Was CAR-T therapy a bystander or driver of lymphoma? Researchers examine first published case A theoretical risk of the immunotherapy became more plausible and sparked an FDA investigation. But many questions remain. By Angus Chen STAT+ | Historic approval of sickle cell gene therapies met with cautious optimism by experts at ASH Many applauded the historic approvals but also questioned whether these cutting-edge treatments will reach the patients who need them most. By Jonathan Wosen STAT+ | CAR-T, recently used in a lupus patient, helps other autoimmune patients, too, in small study In the study, doctors treated eight patients for lupus, four for systemic sclerosis, and three for inflammatory myositis. By Angus Chen David L. Ryan/Globe Staff STAT+ | Opinion: Dana-Farber CEO Laurie Glimcher has always been a trailblazer and a risk taker How Laurie Glimcher ended up taking the greatest risk of her career: breaking up Dana Farber and Brigham & Women's Hospital. By Shirley Leung

More around STAT

Check out more exclusive coverage with a STAT+ subscription Read premium in-depth biotech, pharma, policy, and life science coverage and analysis with all of our STAT+ articles.

---

Enjoying Cancer Briefing? Tell us about your experience Continue reading the latest health & science news with the STAT app Download on the App Store or get it on Google Play

STAT, 1 Exchange Place, Boston, MA ©2023, All Rights Reserved. I no longer wish to receive STAT emails

Update Newsletter Preferences     •    Contact Us     •    Advertise with Us     •    View in Browser